NCT05644041View on ClinicalTrials.gov

Intravesical Gem/Doce in Patients With NMIBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Urinary Bladder Cancer
Interventions
DRUG

gemcitabine + docetaxel

The study drugs, Gemcitabine and Docetaxel, will be administered intravesically at 1000 mg and 40 mg, respectively.

Trial Locations (1)

85721

RECRUITING

University of Arizona Cancer Center, Tucson

All Listed Sponsors
lead

University of Arizona

OTHER